ABL Diagnostics, a Euronext-listed company based in Woippy, France, has announced the execution of a distribution agreement with PALEX, a healthcare company based in Spain. This agreement grants PALEX the rights to offer ABL Diagnostics products to laboratories in Spain.
The collaboration between ABL Diagnostics and PALEX will be carried out through a close partnership with ABL TherapyEdge SL Spain, an affiliate of ABL Diagnostics. The technical and commercial teams of both companies will work together to optimize the user experience for laboratories interested in implementing ABL Diagnostics kits or software in Spain.
As an experienced partner with more than 65 years of experience in the health sector, Palex will be able to offer end-to-end solutions using innovative NGS systems. They will also be able to offer ABL Diagnostics products to laboratories using alternative sequencing techniques like Sanger.
“We are excited to partner with PALEX to expand our presence in Spain. This new collaboration will be a valuable asset for laboratories looking to access our innovative technology, which has already been used successfully in the country through collaborations with key opinion leaders and national institutions,” said Ronan Boulme, ABL Diagnostics GRC Director.
Jaume Clariana, In Vitro Diagnostic Manager at PALEX, added, “The ability to offer sequencing-based solutions to microbiology laboratories has become increasingly important due to the COVID-19 pandemic. Through our network of suppliers, PALEX can offer end-to-end solutions to hospitals and laboratories involved in managing infectious diseases. This partnership with ABL Diagnostics and its Spanish affiliate is a strategic asset for our company, and we are proud to join forces to introduce the DeepChek® technology in Spain.”
The terms of the distribution agreement have not been disclosed.
ABL Diagnostics is a leading international company that offers innovative and proprietary molecular biology assays and end-to-end solutions for molecular detection and genotyping. Their products include assays for HIV, SARS-CoV-2, tuberculosis, viral hepatitis, and other viral and bacterial targets. They also develop kits for clinical specimen collection and digital solutions like Nadis®, an electronic medical record system.
PALEX is a healthcare company with over 65 years of experience in the field. They focus on introducing new solutions to the healthcare sector by tailoring technological advancements to the conditions of each hospital, service, and professional. Their solutions cover a wide range of areas, including heart valves, patient monitoring, dialysis, autotransfusion, surgical robots, and cancer screening, among others.
The collaboration between ABL Diagnostics and PALEX is expected to bring significant advancements in the healthcare sector in Spain. Both companies are committed to providing innovative and sustainable solutions to improve patient outcomes and well-being.
Contact information:
ABL Diagnostics
Chalom Sayada
General Manager
Tel.: +33 7 83 64 68 50
info@abldiagnostics.com
PALEX
Jaume Clariana
Specialized Unit Manager
In Vitro Diagnostics
Tel: +34 6 39 65 88 94
j.clariana@palex.es
Forward-looking statement:
This press release may contain forward-looking statements regarding ABL Diagnostics and its business. These statements are based on assumptions that ABL Diagnostics deems reasonable, but there is no guarantee that they will be verified. They are subject to numerous risks, including those listed in the “Risk Factors” section of the company’s universal registration document filed with the AMF on July 12, 2022 (available on the company’s website). The forward-looking statements in this press release are also subject to risks that are not yet known to ABL Diagnostics or not currently considered material. The occurrence of any of these risks could cause actual results, financial conditions, performance, or achievements to differ significantly from the forward-looking statements.
This press release and the information contained herein do not constitute an offer or invitation to sell or subscribe to ABL Diagnostics shares in any country. The distribution of this press release may be subject to local restrictions, and individuals in possession of this press release should be aware of and comply with these restrictions.
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.